Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness

NCT06707389 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Sudden Deafness
Sensorineural Hearing Loss

Interventions

BIOLOGICAL: autologous blood monocyte vesicles (lower dose)
DRUG: Methylprednisolone
BIOLOGICAL: autologous blood monocyte vesicles (higher dose)

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University